R 
Revvity RVTY · USD
Health Care · Life Sciences Tools & Services · US listing · 🇺🇸 United States
S&P 500
160.72
+3.62%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$2.86bn
FY2016FY2025
Net income
$241.7m
FY2016FY2025
Free cash flow
$508.3m
FY2016FY2025
Shareholders' equity
$7.25bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86bn | $2.76bn | $2.75bn | $3.31bn | $3.83bn | $3.78bn | $2.88bn | $2.78bn | $2.26bn | $2.12bn |
| Gross profit | $1.52bn | $1.32bn | $1.32bn | $1.76bn | $2.28bn | $1.99bn | $1.29bn | $1.25bn | $1.03bn | $972.3m |
| Research and development | $215.8m | $196.8m | $216.6m | $221.6m | $200.3m | $205.4m | $189.3m | $186.1m | $139.2m | $123.8m |
| Operating income | $356.6m | $410.5m | $399.5m | $781.1m | $1.34bn | $956.1m | $405.5m | $371.0m | $304.6m | $305.7m |
| Net income | $241.7m | $295.8m | −$118.4m | $569.2m | $943.2m | $728.1m | $227.6m | $238.8m | $113.0m | $233.7m |
| Diluted earnings per share | 2.13 | 2.43 | -0.96 | 4.50 | 7.44 | 6.47 | 2.04 | 2.14 | 1.02 | 2.12 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $12.17bn | $12.39bn | $13.56bn | $14.13bn | $15.00bn | $7.96bn | $6.54bn | $5.98bn | $6.09bn | $4.28bn |
| Cash and short-term investments | $919.9m | $1.16bn | $1.60bn | $454.4m | $603.3m | $402.0m | $191.9m | $163.1m | $202.1m | $359.3m |
| Total liabilities | $4.92bn | $4.73bn | $5.69bn | $6.75bn | $7.86bn | $4.22bn | $3.72bn | $3.39bn | $3.59bn | $2.12bn |
| Debt | $3.22bn | $3.17bn | $3.90bn | $4.43bn | $5.01bn | $2.03bn | $2.11bn | $16.4m | $2.01bn | $1.2m |
| Shareholders' equity | $7.25bn | $7.67bn | $7.87bn | $7.38bn | $7.14bn | $3.74bn | $2.81bn | $2.58bn | $2.50bn | $2.15bn |
| Shares outstanding | 113m | 122m | 123m | 126m | 127m | 113m | 112m | 112m | 110m | 110m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $581.8m | $628.3m | $91.3m | $679.8m | $1.41bn | $892.2m | $363.5m | $311.0m | $288.5m | $350.6m |
| Capital spending | −$73.5m | −$86.6m | −$81.4m | −$85.6m | −$99.9m | −$77.5m | −$81.3m | −$93.3m | −$39.1m | −$31.7m |
| Free cash flow | $508.3m | $541.7m | $9.9m | $594.2m | $1.31bn | $814.7m | $282.1m | $217.8m | $249.4m | $318.9m |
| Dividends paid | −$32.8m | −$34.5m | −$35.0m | −$35.3m | −$32.4m | −$31.2m | −$31.1m | −$31.0m | −$30.8m | −$30.8m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $729.7m | $711.1m | $772.1m | $698.9m | $720.3m | $664.8m | $729.4m | $684.0m |
| Gross profit | $416.9m | $387.7m | $421.7m | $374.6m | $392.6m | $375.5m | $412.3m | $384.8m |
| Operating income | $89.3m | $75.9m | $111.7m | $98.3m | $106.5m | $87.2m | $111.6m | $103.9m |
| Net income | $51.8m | $40.7m | $98.4m | $46.7m | $53.9m | $42.2m | $94.6m | $94.4m |
| Diluted earnings per share | 0.46 | 0.36 | 0.86 | 0.41 | 0.47 | 0.35 | 0.77 | 0.76 |
| Cash from operations | $191.0m | $115.0m | $183.0m | $138.0m | $134.0m | $128.0m | $174.0m | $147.0m |
| Capital spending | −$11.0m | −$19.0m | −$20.0m | −$18.0m | −$18.0m | −$15.0m | −$24.0m | −$22.0m |
| Free cash flow | $180.0m | $96.0m | $163.0m | $120.0m | $116.0m | $113.0m | $150.0m | $125.0m |
| Total assets | $12.05bn | $12.00bn | $12.17bn | $12.14bn | $12.36bn | $12.36bn | $12.39bn | $12.77bn |
| Cash and short-term investments | $1.02bn | $860.3m | $919.9m | $931.4m | $991.8m | $1.14bn | $1.16bn | $1.23bn |
| Debt | $572.2m | $3.21bn | $3.22bn | $2.63bn | $3.21bn | $3.17bn | $3.15bn | $3.19bn |
| Shareholders' equity | $7.23bn | $7.18bn | $7.25bn | $7.38bn | $7.56bn | $7.64bn | $7.67bn | $7.92bn |
Financial ratios
Data as of 4 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | 52.6% |
| Operating margin | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | 25.3% |
| Net margin | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | 19.2% |
| Return on equity | 3.3% | 3.9% | -1.5% | 7.7% | 13.2% | 19.5% |
| Return on assets | 2.0% | 2.4% | -0.9% | 4.0% | 6.3% | 9.1% |
| Free cash flow yield | 3.8% | 3.9% | 0.9% | 4.0% | 7.9% | 5.7% |
| Revenue growth | 3.7% | 0.2% | -16.9% | -13.5% | 1.2% | 31.2% |
| Earnings growth | -18.3% | -349.9% | -120.8% | -39.7% | 29.5% | 220.0% |
| Current ratio | 1.68x | 3.60x | 2.07x | 2.13x | 2.01x | 1.36x |
| Debt to equity | 0.44x | 0.41x | 0.50x | 0.60x | 0.70x | 0.54x |
| Equity ratio | 59.6% | 61.9% | 58.0% | 52.3% | 47.6% | 46.9% |
| Interest coverage | 3.87x | 4.26x | 4.04x | 7.51x | 13.12x | 19.23x |
| R&D as a share of sales | 7.6% | 7.1% | 7.9% | 6.7% | 5.2% | 5.4% |
| Buybacks as a share of market value | 6.9% | 1.5% | 2.4% | 0.2% | -12.6% | -0.8% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -4.8% | -5.5% | 3.1% |
| Operating income | -23.0% | -17.9% | 2.9% |
| Net income | -24.8% | -19.8% | 1.3% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 50.6% | 50.7% | 52.9% | 49.9% |
| Operating margin | 13.7% | 16.7% | 22.0% | 18.8% |
| Net margin | 9.6% | 8.5% | 13.8% | 11.7% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 45.3 | 45.9 | -114.0 | 31.2 | 27.0 | 22.2 | 47.6 | 36.7 | 71.4 | 24.6 |
| Price to sales | 3.8 | 4.9 | 4.9 | 5.3 | 6.7 | 4.3 | 3.8 | 3.2 | 3.6 | 2.7 |
Market value over time
30 Nov 2016 to 2 Oct 2026, in USD
$5.58bn$16.93bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | -12% | 4% | -24% | -27% | 34% | 46% | 26% | 4% | 38% | 2% |
Dividends and splits
Per share, in the currency the company pays
Paid for 36 years. Last went ex-dividend on 23 Oct 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.21 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.